Following the refocusing of the Company's activities, the organisation has been significantly reduced and the total research, development and administrative cost for the 2nd quarter of 2009 has, compared with 2nd quarter of last year, been reduced by 21,1m DKK (2,8m EUR). The year to date saving for the period 1 January to 30 June 2009 compared to the same period in 2008 was 29,7m DKK (4,0 EUR).
The Net Financial Income in the first half of 2009 was 9,6m DKK (1,3m EUR) compared to 6,3m DKK (0,8m EUR) in 2008.
Balance Sheet and Cash Flow
As at June 30 2009, the Company had total assets of 234,6m DKK (31,5m EUR) of which the Cash & Cash Equivalents amounted to 175,4m DKK (23,6m EUR). This cash position is, subject to the Company's receipt of certain milestone payments related to the ongoing collaboration activities, expected to be sufficient to finance the Company's operations beyond 2010.
The total Equity on June 30 2009 amounts to 187,5m DKK (25,2m EUR).
See Income Statement, Balance sheet, Statement of Change in Equity, Cash Flow statement, and Cap Table through this link: http://www.santaris.com/Library/documents/Santaris_Pharma_Interim_Report_1_Ja nuary_to_30_June_2009.pdf
(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)
The Board of Directors and Executive Management today considered and
approved the Interim Report for the period 1 January to 30 June 2009. The
Interim Report, which is unaudited and unreviewed, is presented in accordance
with international accounting standards. We consider the accounting policies
to be appropri
|SOURCE Santaris Pharma|
Copyright©2009 PR Newswire.
All rights reserved